I have my own theory of aging. Here it is.
The version I'd defend, and which I'll call the Conservation Theory of Aging: aging is what falls out when p53 has to pick among three bad options inside the cell, runs into a hard replicative ceiling on the cleanest of them, and evolution refuses to pay the calorie bill for any honest way around it. Three lousy choices, one ceiling, and a stingy referee.
// the three bad options
When a cell senses DNA damage, it picks one of three things to do. It can repair, which means fixing the damage and continuing. It can go senescent, which means stopping division while staying alive. Or it can commit apoptosis, which is the cell's polite term for self-destruction. p53 sits near the center of that decision, biasing the cell one way or another depending on how bad the damage is, what else the cell is dealing with, what the rest of the body is signaling, and a constellation of post-translational marks no one fully understands yet.
p53 isn't the only voice in the room. The broader DNA-damage-response network, the retinoblastoma pathway, the p21/p16 axis, and a few metabolic sensors all push on it. But it's the transcription factor the others mostly route through, and it's the first place to look.
The standard reading is that the three responses are a graded tumor-suppression program. Small damage gets repaired, dicey cells get benched, dangerous cells get executed. Fine, as far as it goes. What it leaves out is that each of the three is buying short-term safety by handing the body a different long-term IOU.
Repair leaves you with mutations. The cell survives, the tissue holds, nothing has to be rebuilt, but repair isn't clean work. What it leaves behind is residual mutation, epigenetic drift, and mitochondrial junk. Over decades, your repaired cells stop being the cells you started with.
Senescence leaves you with inflammation. The cell quits dividing, cancer risk on that line collapses, nothing has to be replaced. A great deal until the bill comes due in your sixties, when senescent cells start secreting the SASP, irritating the neighborhood, and recruiting other cells into joining them.
Apoptosis leaves you with regenerative debt. The damaged cell dies clean and leaves nothing behind, but the body has to put something back where it was. Stem and progenitor cells divide more often to do the replacing, and the replacement isn't free.
// the math of it
The argument from here uses four numbers and one piece of vocabulary. Get those in place first, then we can do the comparison.
The vocabulary. Hayflick and Moorhead's 1961 paper showed that somatic cells stop dividing after a fixed number of rounds: roughly 50 in their original fetal-fibroblast experiments, with later work putting the range at 50--70 depending on cell type, donor age, and growth conditions. I'll call each of those divisions a Hayflick token: a non-refundable replication credit the lineage spends every time one of its cells divides, and runs out of when telomeres get short enough to force replicative senescence. The ATP a cell spends today gets paid back by tomorrow's meals. The token doesn't.
The numbers. Four of them, all from direct measurements in published papers:
(a) Daily ATP turnover, average human cell ≈ 1012--1013 ATP
-- Flamholz, Phillips & Milo 2014, dividing total-body O2 consumption by ~1013 cells
(b) Daily DNA lesions per cell ≈ 104--105
-- Lindahl 1993, the canonical estimate of spontaneous damage load
(c) ATP cost per nucleotide synthesized de novo ≈ ~50 ATP
-- Lynch & Marinov 2015, direct biochemical accounting
(d) ATP cost per mammalian cell division ≈ ~1013 ATP
-- Lynch & Marinov 2015, allometric scaling from E. coli chemostat data to mammalian cell volume
Two of those numbers, (a) and (d), are at the same order of magnitude, which makes physical sense: a cell that doubles on roughly a daily timescale has to spend roughly a day's worth of energy building the next one. That's the central physical fact the whole argument rests on. One cell division costs about one cell-day of total metabolism.
The upper bound on repair cost. I deliberately don't want to estimate this from pathway-frequency assumptions, because the per-pathway fluxes aren't measured directly and any number I'd give would be a guess. The honest move is an upper bound instead. The most expensive single-lesion repair pathway is nucleotide-excision repair, which patches around 30 nucleotides per event. From (c), that's 30 × 50 = 1,500 ATP per lesion, ceiling. Apply that ceiling to every lesion in (b), even though most lesions are handled by cheaper pathways:
105 lesions/day × 1,500 ATP/lesion = 1.5×108 ATP/day
That's the worst case: every lesion gets the most expensive repair. Set it against (a), the daily cell budget of 1012--1013 ATP, and you get 0.0015% to 0.015% of the daily energy budget, ceiling. The real number is lower, because most lesions are handled by single-nucleotide base-excision repair (~50 ATP, roughly 30x cheaper than the NER ceiling). The upper bound alone is enough to make the qualitative point. Yang et al.'s 2021 PNAS Perspective says it outright: "the energy budget of cells remains largely unexplored". Nobody has a measured number for repair as a fraction of cellular ATP, but the upper bound is enough. Rolfe & Brown's canonical 1997 partition of cellular ATP usage doesn't list DNA repair as a line item for the same reason: the partition resolves protein synthesis (25--30%) and ion pumping (20--30%), but its noise floor is at the 1% level. Repair is two orders of magnitude below that floor even at worst case.
The comparison. Now the three responses laid out side by side, in two currencies:
repair ≈ ≤ 1.5×108 ATP/day + 0 Hayflick tokens
senescence ≈ ~0 direct ATP + 0 tokens; inflammation bill comes due later
apoptosis & replace ≈ ~1013 ATP (one full cell-day of metabolism) + 1 Hayflick token
cost ratio: one division / one day of repair ≈ 1013 / 1.5×108 ≈ 6.7×104×
So an apoptosis-and-replace event costs the body about sixty-five thousand days of upper-bound repair work on the cell that got killed, and that's against the ceiling. Against the realistic per-day repair load, the ratio is bigger by another order of magnitude or two. Plus a Hayflick token from the replacing lineage, which doesn't get refunded.
Senescence is even more interesting in this frame. The cell that goes senescent pays nothing directly. No replacement, no Hayflick token, no immediate metabolic cost. The bill is paid decades later, by other cells, as the SASP irritates the tissue around it. SASP costs are diffuse, smeared across the tissue and time-shifted by decades, which is why selection lets the cell keep choosing them and why senescent burden piles up the way it does.
This is where the theory's name comes from. The cell is structurally conservative. The rule it follows isn't "minimize damage". If it were, repair would have a clean fraction in Rolfe & Brown's partition, and it doesn't, because repair is four or five orders of magnitude cheaper than a division. The rule the cell actually follows is closer to "minimize divisions, because every division costs a full day of metabolism plus a non-refundable Hayflick token, while a day of repair barely registers." Repair is cheap on both axes.
// the part I'm less sure about
The native p53 setting is the one that minimizes ATP-plus-Hayflick spend under ancestral conditions. Lower the apoptotic threshold and the Hayflick budget burns down faster: you spend tokens and a day's metabolism per replacement to dispose of cells that the conservative setting would have repaired for a tiny fraction of either. Raise the threshold and the mutation and senescent piles get higher instead. The native p53 bias we're all born running is whatever balance kept those two debts roughly equal across an ancestral lifespan. Not a careful trade, just the setting selection happened to land on and stop tuning.
Don't push the apoptotic threshold harder. Break the coupling between the two costs. Pair the threshold change with telomerase, so the Hayflick token gets refunded each time you spend one. The ATP cost stays. The lineage exhaustion doesn't.
// evolution didn't because evolution couldn't afford it
You could build a body that doesn't have this problem. Push p53 toward apoptosis, install telomerase upkeep so the Hayflick ceiling stops biting, beef up the stem-cell reserves and the protein-clearance machinery and the mitochondrial quality control so they can absorb the higher turnover. Senescent burden drops. Mutation burden drops. Regenerative reserve holds. The body runs hotter and outlasts its predecessor.
Evolution didn't install that body for an unromantic reason: it eats too much. A resting human already spends most of 1500--2000 kcal/day on cellular housekeeping. Add more apoptotic flux, telomere upkeep, sharper proteostasis, faster mitochondrial turnover, and you're looking at tens of percent more, conservatively, possibly much more depending on the tissue. In any environment where calories are the binding constraint, selection punishes that body harder than it ever rewards post-reproductive longevity, which it more or less can't see. Evolution declined to pay. Aging is what falls out when the upgrade doesn't get installed.
This is the disposable-soma idea, made specific. Kirkwood describes the soma-vs-germline tradeoff at the level of resource allocation. The Conservation Theory says which molecule implements the tradeoff (p53), which ceiling it's pressed against (Hayflick), and what currency evolution refused to spend (calories).
// the rest of this notebook is the upgrade
If the picture is right, then the "secret" to longer life is less about patching damage and more about whether you can buy back the body that scarcity refused to build. Move the p53 bias, pay the Hayflick cost with telomerase, and pair both with the downstream machinery that can absorb higher turnover.
The constraint that shaped the original deal, calories, isn't really binding anymore. Global caloric supply per capita has roughly tripled since industrialization. AI, robotics, and industrial automation keep pushing food, energy, and material abundance cheaper. The thing getting scarcer every year is time. Evolution optimized humans around energetic scarcity because it had to. In a future that can run gene and cell therapies that extend healthy lifespan by multiples, the marginal cost of sustaining a body longer is negligible, especially with birth rates falling. Trading future surplus for more years of healthy life is exactly the move evolution was never allowed to make. Doing it deliberately, through engineering, is what comes next.
What's open: the relative weights on mutation, inflammation, and regenerative debt. The actual size of the energy gap. Whether the senescence branch can be edited out without something downstream breaking. All of it.